Highlights OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Delayed OTC Markets Other stock markets 07:14:15 09/05/2024 pm IST			5-day change	1st Jan Change
0.0003 ^USD	0.00%		0.00%	0.00%

2023	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
2023	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program	16/23/16	CI
OncoSec Medical Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma Refractory to Anti-PD-1 Treatment	03/23/03	CI
OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	14/23/14	CI
OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	14/23/14	CI
OncoSec Medical Incorporated Reports Earnings Results for the First Quarter Ended October 31, 2022	16/22/16	CI
OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma	16/22/16	CI
Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment	11/22/11	CI
Reverse Split: 1 of 22	09/22/09	FA
OncoSec Medical Incorporated Reports Earnings Results for the Full Year Ended July 31, 2022	01/22/01	CI
OncoSec Medical Incorporated Announces Pipeline Prioritization	05/22/05	CI
OncoSec Medical Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	15/22/15	CI
OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022	16/22/16	CI
OncoSec Medical Incorporated Reports Earnings Results for the First Quarter Ended October 31, 2021	16/21/16	CI
OncoSec Medical Incorporated Reports Earnings Results for the Full Year Ended July 31, 2021	30/21/30	CI
Oncosec Medical Incorporated Enters into Clinical Research Cooperation Agreement with Merck to Conduct Global Phase III Study of Interleukin-12 (IL-12) Plasmid DNA Drug Tavo™ in Combination with the Anti-PD-1 Drug Keytruda® (Pembrolizumab) in Advanced Metastatic Melanoma	09/21/09	CI
OncoSec Medical Incorporated : , Merck Team Up for Late-Stage Metastatic Melanoma Trial -- OncoSec Jumps 27% After-Hours	07/21/07	MT
OncoSec Medical Incorporated Enters into A Collaboration Agreement with Merck for Pivotal Global Phase 3 Study, Keynote-C87, of Tavo™ Combined with Keytruda® for Late-Stage Metastatic Melanoma	07/21/07	CI
Oncosec Medical Incorporated Reports Earnings Results for the Third Quarter Ended April 30, 2021	12/21/12	CI
OncoSec Medical Incorporated to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma	15/21/15	CI
Oncosec Medical Incorporated Reports Earnings Results for the Second Quarter Ended January 31, 2021	15/21/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Highlights

Filters